Brokers Offer Predictions for BEAM FY2026 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Beam Therapeutics in a research report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio expects that the company will earn ($3.30) per share for the year. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ FY2027 earnings at ($3.00) EPS and FY2028 earnings at ($1.91) EPS.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.01). Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company had revenue of $14.30 million for the quarter, compared to analysts’ expectations of $14.52 million. During the same quarter last year, the company earned ($1.22) EPS. Beam Therapeutics’s revenue for the quarter was down 16.9% compared to the same quarter last year.

BEAM has been the subject of a number of other reports. Wedbush reissued an “outperform” rating and issued a $57.00 target price on shares of Beam Therapeutics in a research report on Monday, January 13th. Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $27.00 to $39.00 in a report on Wednesday, November 6th. Leerink Partnrs raised shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Scotiabank began coverage on shares of Beam Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $24.00 price target for the company. Finally, Cantor Fitzgerald upgraded shares of Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $47.67.

Beam Therapeutics Price Performance

Shares of NASDAQ:BEAM opened at $27.65 on Wednesday. The company’s fifty day moving average price is $26.49 and its 200 day moving average price is $25.77. The firm has a market capitalization of $2.29 billion, a P/E ratio of -15.71 and a beta of 1.92. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $49.50.

Institutional Trading of Beam Therapeutics

Several institutional investors have recently added to or reduced their stakes in BEAM. Vestmark Advisory Solutions Inc. grew its position in shares of Beam Therapeutics by 29.3% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 173,152 shares of the company’s stock valued at $4,482,000 after buying an additional 39,250 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Beam Therapeutics in the fourth quarter valued at approximately $703,000. Proficio Capital Partners LLC acquired a new stake in shares of Beam Therapeutics during the 4th quarter worth approximately $406,000. Atria Investments Inc boosted its position in Beam Therapeutics by 17.1% during the 4th quarter. Atria Investments Inc now owns 9,562 shares of the company’s stock valued at $237,000 after purchasing an additional 1,395 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Beam Therapeutics by 3.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 648,945 shares of the company’s stock worth $16,094,000 after buying an additional 19,453 shares during the last quarter. Institutional investors own 99.68% of the company’s stock.

Insider Activity

In other Beam Therapeutics news, insider Christine Bellon sold 1,241 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the sale, the insider now owns 102,968 shares in the company, valued at $2,541,250.24. This represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO John M. Evans sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now directly owns 908,659 shares in the company, valued at approximately $24,306,628.25. This represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.